Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

Dyne Therapeutics (DYN)

Dyne Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:DYN
DateTimeSourceHeadlineSymbolCompany
13/06/202421:40GlobeNewswire Inc.Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research CongressNASDAQ:DYNDyne Therapeutics Inc
12/06/202400:42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DYNDyne Therapeutics Inc
12/06/202400:41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DYNDyne Therapeutics Inc
12/06/202400:34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DYNDyne Therapeutics Inc
11/06/202421:32Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DYNDyne Therapeutics Inc
11/06/202421:25Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DYNDyne Therapeutics Inc
11/06/202421:22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DYNDyne Therapeutics Inc
30/05/202412:30GlobeNewswire Inc.Dyne Therapeutics to Present at Jefferies Global Healthcare ConferenceNASDAQ:DYNDyne Therapeutics Inc
28/05/202412:30GlobeNewswire Inc.Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional SharesNASDAQ:DYNDyne Therapeutics Inc
24/05/202422:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DYNDyne Therapeutics Inc
24/05/202422:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DYNDyne Therapeutics Inc
24/05/202422:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DYNDyne Therapeutics Inc
23/05/202402:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DYNDyne Therapeutics Inc
22/05/202421:30Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:DYNDyne Therapeutics Inc
22/05/202412:59Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DYNDyne Therapeutics Inc
22/05/202401:39GlobeNewswire Inc.Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common StockNASDAQ:DYNDyne Therapeutics Inc
20/05/202423:00Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DYNDyne Therapeutics Inc
20/05/202421:24Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:DYNDyne Therapeutics Inc
20/05/202421:01GlobeNewswire Inc.Dyne Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:DYNDyne Therapeutics Inc
20/05/202412:37Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DYNDyne Therapeutics Inc
20/05/202411:30GlobeNewswire Inc.Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional EndpointsNASDAQ:DYNDyne Therapeutics Inc
19/05/202413:00GlobeNewswire Inc.Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ETNASDAQ:DYNDyne Therapeutics Inc
18/05/202402:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DYNDyne Therapeutics Inc
18/05/202402:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DYNDyne Therapeutics Inc
18/05/202402:03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DYNDyne Therapeutics Inc
16/05/202421:26Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DYNDyne Therapeutics Inc
16/05/202421:23Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DYNDyne Therapeutics Inc
16/05/202421:18Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DYNDyne Therapeutics Inc
02/05/202421:10GlobeNewswire Inc.Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:DYNDyne Therapeutics Inc
27/03/202420:05GlobeNewswire Inc.Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive OfficerNASDAQ:DYNDyne Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:DYN